Premarket News

According to TheFly, the firm maintained its ‘Overweight’ rating on the stock after a conversation with an advertising monetization expert.

Lunai is acquiring $20 million in blood-brain barrier delivery tech and Alzheimer’s assets from Clemann Group.

BMO analysts raised their price target on NAVN stock to $15 from $13, reaffirming an ‘Outperform’ rating.

Ethereum, Dogecoin, and Solana each fell more than 5%, leading losses among top cryptocurrencies.

Instead of using cash to make the down payment on a mortgage, home buyers can get a separate loan that uses Bitcoin or the stablecoin USDC as collateral.

In the fourth quarter, Pony.ai reported an 18% drop in total revenue, though the figure still came in ahead of Street estimates, according to Fiscal.ai data.

The company will deploy its AI-powered EEG/ERP system to assess and treat brain injuries in service members and veterans.

The Independent Data Monitoring Committee reviewed interim data from 183 evaluable patients, about half of the 366 participants enrolled in the Phase 2b study.

The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.

Analysts say the potential $75B debut could become one of the most sought-after listings in market history.

Allegations claim the tech giant masked the impact of crypto mining on GPU sales in 2017 and 2018.

The company said its Phase 3 trial to treat diabetic retinopathy met its primary endpoint.

Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its short report on Tuesday.

Traders linked the move to the company’s low float, a recently concluded reverse stock split, and an equity offering.

SMCI had gained by over 17% in the past three sessions.

Barclays warned that disruptions in Hormuz could remove 13-14 million bpd, with Brent possibly rising toward $110 if the disruptions persist.

Meta and YouTube lost a closely watched trial, with a jury finding that their platforms harmed a young user through addictive design features that contributed to her mental health distress.

Sentiment was also lifted by expectations tied to the Golden Dome missile-defense initiative, which could boost demand for satellite and space infrastructure.

The recent merger shifts the company beyond its legacy business into sports media, live events, and branded experiences.

Data from Stocktwits shows that traders remain ‘extremely bearish’ on SPY and QQQ.

Microsoft is the worst performer among the “Magnificent Seven” stocks this year.

According to Stocktwits data, retail chatter around CELH stock has risen 2356% over the last three months.

Earlier this week, a bill proposing to ban sports betting on Kalshi and Polymarket lifted DKNG and FLUT shares, but TD Cowen now says such measures are unlikely to pass in the current legislative session.

The new council will be co-chaired by David Sacks and Michael Kratsios, both former government advisors.

The company said it produced its first kilogram of 99.9% pure terbium oxide, just months after producing another heavy rare-earth metal domestically.

The U.S. Food and Drug Administration indicated that a single Phase 3 trial of QRX003 could be enough to support approval in the U.S.

The company said its tender offer includes notes due from 2031 through 2035, and that the offer will expire on March 31, 2026.

The MAVAN project was originally developed to help Bitmine stake its own Ethereum holdings, but the company is now expanding the scope to institutional investors, custodians, and other ecosystem partners.

The treatments, known as SRP-1001 and SRP-1003, are being studied for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively.

The cryptocurrency and stock markets rose in early-morning trade on Wednesday after reports of a possible peace deal between the U.S. and Iran.

The company said it has developed a new liquid biopsy method, and in a blinded validation cohort, it achieved over 95% sensitivity for stage I & II cancers with 95% specificity.

The company began Phase I operations under its joint venture with Maddox Defense, which includes setting up a defense manufacturing facility in Texas.

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

The biotech firm’s Phase 1/2 trial data for its gene-editing therapy BEAM-302 showed marked improvement in patients with AAT deficiency.

Bitcoin's price held above $71,000 in early morning trade on Wednesday, recovering from a drop below $69,000 in the previous session.

The agreement builds on a $4.94 billion contract that was awarded to Lockheed Martin in March 2025 to produce additional Precision Strike Missiles.

At the core of the deal is Terns’ investigational drug TERN-701, an oral therapy designed to address mutations associated with chronic myeloid leukemia.

The proposal needs the backing of Senate Majority Leader John Thune and the approval of President Donald Trump, the report added.

Mining has become less lucrative, losing $16,800 for each Bitcoin.

Sandisk completed a private placement deal with Nanya Technology Corp., aiming to secure a minority stake as part of a wider partnership.

SMCI shares have ended in the green over the past two days.

Analysts said the war risk premium is still ebbing and flowing, with some expecting stabilization if escalation risks ease.

Despite the bounce, data from Stocktwits shows that traders remain ‘extremely bearish’ on SPY and QQQ.

GameStop's revenue and profit declined in the fourth quarter.

The analyst said that Arm's new strategy positions the firm between hyperscaler-built custom chips and traditional x86 servers, challenging Intel and AMD.

Karyopharm drew strong retail interest after reporting Phase 3 results for its rare bone marrow cancer treatment and announcing a $30 million private placement deal.

Ocugen said 12-month Phase 2 trial data showed its drug OCU410 significantly reduced lesion growth at the dose planned for Phase 3.

The company said this allows Li Auto to buy back shares from the date of authorization to March 31, 2027.

The company said its subsidiary, SVM Machining, completed ITAR registration, a U.S. State Department-regulated framework governing defense-related technologies.